Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Multiple myeloma is a plasma cell malignancy characterized by recurrentIgHtranslocations and well described genomic heterogeneity. Although transcriptome profiles in multiple myeloma has been described, landscape of expressed fusion genes and their clinical impact remains unknown. To provide a comprehensive and...
Multiple Myeloma Multiplemyelomais a plasma cellmalignancycharacterized by monoclonalprotein secretion, excessive osteoclastic activity and inhibition of osteoblastic bone formation. This set of characteristics leads to progressive and destructive osteolyticbone diseasemanifesting asosteolytic lesionsand severe oste...
Multiple myeloma is a plasma cell skeletal malignancy. While therapeutic agents such as bortezomib and lenalidomide have significantly improved overall survival, the disease is currently incurable with the emergence of drug resistance limiting the efficacy of chemotherapeutic strategies. Failure to cure the...
Multiple myeloma is an incurable plasma cell malignancy that is mostly restricted to the bone marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor site may be responsible for immune evasion and therapeutical failure of immunotherapies. Therefore, enhanced knowledge about the actual stat...
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is terme
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by immunosuppression. In this study, we identified factors in patients’ bone marrow (BM) sera inhibiting autologous anti-MM immunity and developed an ex vivo strategy for inducing MM-specific cytotoxic T lymphocytes (CTLs)....
1 Multiple myeloma (MM) is a plasma cell (PC) malignancy of terminally differentiated B lymphocytes. 2 The co-occurrence of MM and MPN is rare. There are a few reports of ET co-occurring with MM,3, 4, 5 with MM manifesting simultaneously with or several years after ET. PV combined ...
Multiple myeloma. Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a histor... RA Kyle,SV Rajkumar - 《Blood》 被引量: 1015发表: 2008年 Consolidation Therapy With Low-Dose Thalidomide and ...
Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and promote regulatory T-cell (Treg) differentiation. It is presently unknown whether MM cells...